What’s new?

The American College of Physicians (ACP) published an updated 2023 guideline on drug therapy for patients with reduced bone density or osteoporosis. An extensive secondary analysis published last year has been incorporated as the evidence base. A bottom line of the new ACP guidelines is that the place of bisphosphonates as first-line therapy has been strengthened.